Medical Condition News

RSS

OptiMedica launches Catalys Precision Laser System in the US

Global ophthalmic company OptiMedica Corp. has announced the launch of its Catalys Precision Laser System in the United States, with the first patient cases performed by Drs. Mike and Paul Mann at the Mann Eye Institute in Houston.

27 Feb 2012

Restoration Robotics ARTAS hair transplantation system receives Canadian Medical Device License

Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS System has received a Canadian Medical Device License and can now be marketed and sold within Canada.

27 Feb 2012

Death of myelin sheath producing cells does not trigger MS

Millions of adults suffer from the incurable disease multiple sclerosis (MS). It is relatively certain that MS is an autoimmune disease in which the body's own defense cells attack the myelin in the brain and spinal cord.

27 Feb 2012

Collaborative study of physical activity patterns, eating habits in colorectal cancer patients

The five hospitals of Meridian Health, a System Partner of The Cancer Institute of New Jersey (CINJ), have joined forces with CINJ in offering a clinical research study that examines physical activity patterns and eating habits in colorectal cancer patients who have recently finished treatment.

27 Feb 2012

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

27 Feb 2012

New drug improves glycaemic control with minimum risk of hypoglycemia in type 2 diabetics

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012

EMA acceptance of peginesatide MAA triggers $5M milestone payment to Affymax

Affymax, Inc. today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.

27 Feb 2012

First patients in Germany treated with Delcath Hepatic CHEMOSAT Delivery System

Delcath Systems, Inc., announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.

27 Feb 2012

Gallup-Healthways WBI data shows decline in the U.S. obesity rates

Adult obesity in America has plateaued and may be slowly declining, according to data from The Gallup-Healthways Well-Being Index (WBI) presented today at the Population Health and Care Coordination Colloquium in Philadelphia. The obesity rate in America fell in 2011 to 26.1 percent, from 26.6 percent in 2010 and 26.5 percent in 2009.

27 Feb 2012

Aesculap, Osseon partner to distribute VCF treatment devices

Osseon Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex SB (steerable balloon) in select regions of Europe and Asia.

From B. Braun Melsungen AG 27 Feb 2012

ATI commences European trial of neurostimulation system for migraine

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable stimulator for severe headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine.

27 Feb 2012

GSK, Angiochem to develop and commercialize LSD treatments

Angiochem announced today a global collaboration with GlaxoSmithKline (GSK) to discover, develop and commercialize treatments for lysosomal storage diseases.

27 Feb 2012

H2S transforms dental pulp stem cells into liver cells

Japanese scientists have found that the odorous compound responsible for halitosis - otherwise known as bad breath - is ideal for harvesting stem cells taken from human dental pulp.

27 Feb 2012

Montefiore director to host Twitter chat about neuroendocrine tumors on Feb. 29

On February 29, which is Rare Disease Day, Steven Libutti, MD, Vice Chairman of Surgery and Director of the Montefiore Einstein Center for Cancer Care will host a Twitter chat about the signs and symptoms, diagnosis and treatment of neuroendocrine tumors, or NETs, a rare form of cancer.

27 Feb 2012

Chronic pain patients at high-risk for comorbid substance abuse benefit from 3-week program

Research presented at the American Academy of Pain Medicine's 28th Annual Meeting shows that substance use education incorporated into a cognitive behavioral rehabilitation programming is effective to improve pain and function for the chronic pain patient at high-risk for comorbid substance abuse.

27 Feb 2012

KF scientist to speak at William Paterson University, March 1

John DeLuca, PhD, vice president for research at Kessler Foundation, is the featured speaker at the grand opening of the new Science Complex at William Paterson University's College of Science and Health. Dr. DeLuca, a well known expert in cognitive function, will discuss "Neuroimaging, Brain and Behavior: New Opportunities for the Future," on March 1, 2012 12:30 to 1:05 pm in the Science East Lecture Hall.

27 Feb 2012

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

A Saint Louis University investigator noted for her pain research is working to reduce a painful chemotherapy side effect, thanks to a $126,500 grant from the Mayday Fund, an organization dedicated to alleviating the incidence, degree and consequence of human physical pain.

27 Feb 2012

New method can predict whether Tylenol-poisoning patients need liver transplant

University of Utah mathematicians developed a set of calculus equations to make it easier for doctors to save Tylenol overdose patients by quickly estimating how much painkiller they took, when they consumed it and whether they will require a liver transplant to survive.

27 Feb 2012

CML patients can benefit from imatinib after unsuccessful interferon therapies

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib.

27 Feb 2012